Adverse Outcome Pathway on Aryl hydrocarbon receptor activation leading to uroporphyria:
Hepatic uroporphyria is a disorder where the disturbance of heme biosynthesis results in accumulation and excretion of uroporphyrin, heptacarboxyl- and hexacarboxyl porphyrin: collectively referred to as highly carboxylated porphyrins (HCPs). The disorder is due to a homozygous mutation in uroporphy...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | , , |
| Format: | Electronic eBook |
| Language: | English |
| Published: |
Paris
OECD Publishing
2019
|
| Series: | OECD Series on Adverse Outcome Pathways
|
| Subjects: | |
| Online Access: | Volltext |
| Summary: | Hepatic uroporphyria is a disorder where the disturbance of heme biosynthesis results in accumulation and excretion of uroporphyrin, heptacarboxyl- and hexacarboxyl porphyrin: collectively referred to as highly carboxylated porphyrins (HCPs). The disorder is due to a homozygous mutation in uroporphyrinogen decarboxylase (UROD), an enzyme involved in the heme biosynthesis pathway, or may be chemically induced, which involves the inhibition of UROD. This AOP describes the linkages leading to chemically induced porphyria through the activation of the aryl hydrocarbon receptor (AHR), a ligand-activated transcription factor. AHR activation leads to the induction of cytochrome P450 1A2, a phase I metabolising enzyme, which in turn results in excessive oxidation of uroporphyrinogen. This oxidation produces a UROD inhibitor, preventing the conversion of uroporphyrinogen to coprouroporphyrinogen and increasing the synthesis of the UROD inhibitor in a positive feedback loop. The accumulation of uroporphyrinogen leads to its preferential oxidation and accumulation of HCP in various organs (Uroporphyria) |
| Physical Description: | 1 Online-Ressource (78 Seiten) |
| DOI: | 10.1787/fde13d2c-en |
Staff View
MARC
| LEADER | 00000nam a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV047934504 | ||
| 003 | DE-604 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 220413s2019 xx o|||| 00||| eng d | ||
| 024 | 7 | |a 10.1787/fde13d2c-en |2 doi | |
| 035 | |a (ZDB-13-SOC)061279242 | ||
| 035 | |a (OCoLC)1312690767 | ||
| 035 | |a (DE-599)BVBBV047934504 | ||
| 040 | |a DE-604 |b ger |e aacr | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-384 |a DE-91 |a DE-473 |a DE-824 |a DE-29 |a DE-739 |a DE-355 |a DE-20 |a DE-1028 |a DE-1049 |a DE-188 |a DE-521 |a DE-861 |a DE-898 |a DE-92 |a DE-573 |a DE-19 | ||
| 100 | 1 | |a Farhat, Amani |e Verfasser |4 aut | |
| 245 | 1 | 0 | |a Adverse Outcome Pathway on Aryl hydrocarbon receptor activation leading to uroporphyria |c Amani Farhat ... [et al] |
| 264 | 1 | |a Paris |b OECD Publishing |c 2019 | |
| 300 | |a 1 Online-Ressource (78 Seiten) | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 490 | 0 | |a OECD Series on Adverse Outcome Pathways | |
| 520 | |a Hepatic uroporphyria is a disorder where the disturbance of heme biosynthesis results in accumulation and excretion of uroporphyrin, heptacarboxyl- and hexacarboxyl porphyrin: collectively referred to as highly carboxylated porphyrins (HCPs). The disorder is due to a homozygous mutation in uroporphyrinogen decarboxylase (UROD), an enzyme involved in the heme biosynthesis pathway, or may be chemically induced, which involves the inhibition of UROD. This AOP describes the linkages leading to chemically induced porphyria through the activation of the aryl hydrocarbon receptor (AHR), a ligand-activated transcription factor. AHR activation leads to the induction of cytochrome P450 1A2, a phase I metabolising enzyme, which in turn results in excessive oxidation of uroporphyrinogen. This oxidation produces a UROD inhibitor, preventing the conversion of uroporphyrinogen to coprouroporphyrinogen and increasing the synthesis of the UROD inhibitor in a positive feedback loop. The accumulation of uroporphyrinogen leads to its preferential oxidation and accumulation of HCP in various organs (Uroporphyria) | ||
| 650 | 4 | |a Environment | |
| 650 | 4 | |a Social Issues/Migration/Health | |
| 700 | 1 | |a Manning, Gillian |4 ctb | |
| 700 | 1 | |a O'Brien, Jason |4 ctb | |
| 700 | 1 | |a Kennedy, Sean W... |4 ctb | |
| 856 | 4 | 0 | |u https://doi.org/10.1787/fde13d2c-en |x Verlag |z kostenfrei |3 Volltext |
| 912 | |a ZDB-13-SOC | ||
| 943 | 1 | |a oai:aleph.bib-bvb.de:BVB01-033315998 | |
Record in the Search Index
| _version_ | 1818806052218470400 |
|---|---|
| adam_text | |
| adam_txt | |
| any_adam_object | |
| any_adam_object_boolean | |
| author | Farhat, Amani |
| author2 | Manning, Gillian O'Brien, Jason Kennedy, Sean W.. |
| author2_role | ctb ctb ctb |
| author2_variant | g m gm j o jo s w k sw swk |
| author_facet | Farhat, Amani Manning, Gillian O'Brien, Jason Kennedy, Sean W.. |
| author_role | aut |
| author_sort | Farhat, Amani |
| author_variant | a f af |
| building | Verbundindex |
| bvnumber | BV047934504 |
| collection | ZDB-13-SOC |
| ctrlnum | (ZDB-13-SOC)061279242 (OCoLC)1312690767 (DE-599)BVBBV047934504 |
| discipline | Wirtschaftswissenschaften |
| discipline_str_mv | Wirtschaftswissenschaften |
| doi_str_mv | 10.1787/fde13d2c-en |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>00000nam a2200000zc 4500</leader><controlfield tag="001">BV047934504</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">220413s2019 xx o|||| 00||| eng d</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1787/fde13d2c-en</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-13-SOC)061279242</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1312690767</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV047934504</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-384</subfield><subfield code="a">DE-91</subfield><subfield code="a">DE-473</subfield><subfield code="a">DE-824</subfield><subfield code="a">DE-29</subfield><subfield code="a">DE-739</subfield><subfield code="a">DE-355</subfield><subfield code="a">DE-20</subfield><subfield code="a">DE-1028</subfield><subfield code="a">DE-1049</subfield><subfield code="a">DE-188</subfield><subfield code="a">DE-521</subfield><subfield code="a">DE-861</subfield><subfield code="a">DE-898</subfield><subfield code="a">DE-92</subfield><subfield code="a">DE-573</subfield><subfield code="a">DE-19</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Farhat, Amani</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Adverse Outcome Pathway on Aryl hydrocarbon receptor activation leading to uroporphyria</subfield><subfield code="c">Amani Farhat ... [et al]</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Paris</subfield><subfield code="b">OECD Publishing</subfield><subfield code="c">2019</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (78 Seiten)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">OECD Series on Adverse Outcome Pathways</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Hepatic uroporphyria is a disorder where the disturbance of heme biosynthesis results in accumulation and excretion of uroporphyrin, heptacarboxyl- and hexacarboxyl porphyrin: collectively referred to as highly carboxylated porphyrins (HCPs). The disorder is due to a homozygous mutation in uroporphyrinogen decarboxylase (UROD), an enzyme involved in the heme biosynthesis pathway, or may be chemically induced, which involves the inhibition of UROD. This AOP describes the linkages leading to chemically induced porphyria through the activation of the aryl hydrocarbon receptor (AHR), a ligand-activated transcription factor. AHR activation leads to the induction of cytochrome P450 1A2, a phase I metabolising enzyme, which in turn results in excessive oxidation of uroporphyrinogen. This oxidation produces a UROD inhibitor, preventing the conversion of uroporphyrinogen to coprouroporphyrinogen and increasing the synthesis of the UROD inhibitor in a positive feedback loop. The accumulation of uroporphyrinogen leads to its preferential oxidation and accumulation of HCP in various organs (Uroporphyria)</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Environment</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Social Issues/Migration/Health</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Manning, Gillian</subfield><subfield code="4">ctb</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">O'Brien, Jason</subfield><subfield code="4">ctb</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kennedy, Sean W...</subfield><subfield code="4">ctb</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1787/fde13d2c-en</subfield><subfield code="x">Verlag</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-13-SOC</subfield></datafield><datafield tag="943" ind1="1" ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-033315998</subfield></datafield></record></collection> |
| id | DE-604.BV047934504 |
| illustrated | Not Illustrated |
| index_date | 2024-07-03T19:35:02Z |
| indexdate | 2024-12-18T19:03:38Z |
| institution | BVB |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-033315998 |
| oclc_num | 1312690767 |
| open_access_boolean | 1 |
| owner | DE-384 DE-91 DE-BY-TUM DE-473 DE-BY-UBG DE-824 DE-29 DE-739 DE-355 DE-BY-UBR DE-20 DE-1028 DE-1049 DE-188 DE-521 DE-861 DE-898 DE-BY-UBR DE-92 DE-573 DE-19 DE-BY-UBM |
| owner_facet | DE-384 DE-91 DE-BY-TUM DE-473 DE-BY-UBG DE-824 DE-29 DE-739 DE-355 DE-BY-UBR DE-20 DE-1028 DE-1049 DE-188 DE-521 DE-861 DE-898 DE-BY-UBR DE-92 DE-573 DE-19 DE-BY-UBM |
| physical | 1 Online-Ressource (78 Seiten) |
| psigel | ZDB-13-SOC |
| publishDate | 2019 |
| publishDateSearch | 2019 |
| publishDateSort | 2019 |
| publisher | OECD Publishing |
| record_format | marc |
| series2 | OECD Series on Adverse Outcome Pathways |
| spelling | Farhat, Amani Verfasser aut Adverse Outcome Pathway on Aryl hydrocarbon receptor activation leading to uroporphyria Amani Farhat ... [et al] Paris OECD Publishing 2019 1 Online-Ressource (78 Seiten) txt rdacontent c rdamedia cr rdacarrier OECD Series on Adverse Outcome Pathways Hepatic uroporphyria is a disorder where the disturbance of heme biosynthesis results in accumulation and excretion of uroporphyrin, heptacarboxyl- and hexacarboxyl porphyrin: collectively referred to as highly carboxylated porphyrins (HCPs). The disorder is due to a homozygous mutation in uroporphyrinogen decarboxylase (UROD), an enzyme involved in the heme biosynthesis pathway, or may be chemically induced, which involves the inhibition of UROD. This AOP describes the linkages leading to chemically induced porphyria through the activation of the aryl hydrocarbon receptor (AHR), a ligand-activated transcription factor. AHR activation leads to the induction of cytochrome P450 1A2, a phase I metabolising enzyme, which in turn results in excessive oxidation of uroporphyrinogen. This oxidation produces a UROD inhibitor, preventing the conversion of uroporphyrinogen to coprouroporphyrinogen and increasing the synthesis of the UROD inhibitor in a positive feedback loop. The accumulation of uroporphyrinogen leads to its preferential oxidation and accumulation of HCP in various organs (Uroporphyria) Environment Social Issues/Migration/Health Manning, Gillian ctb O'Brien, Jason ctb Kennedy, Sean W... ctb https://doi.org/10.1787/fde13d2c-en Verlag kostenfrei Volltext |
| spellingShingle | Farhat, Amani Adverse Outcome Pathway on Aryl hydrocarbon receptor activation leading to uroporphyria Environment Social Issues/Migration/Health |
| title | Adverse Outcome Pathway on Aryl hydrocarbon receptor activation leading to uroporphyria |
| title_auth | Adverse Outcome Pathway on Aryl hydrocarbon receptor activation leading to uroporphyria |
| title_exact_search | Adverse Outcome Pathway on Aryl hydrocarbon receptor activation leading to uroporphyria |
| title_exact_search_txtP | Adverse Outcome Pathway on Aryl hydrocarbon receptor activation leading to uroporphyria |
| title_full | Adverse Outcome Pathway on Aryl hydrocarbon receptor activation leading to uroporphyria Amani Farhat ... [et al] |
| title_fullStr | Adverse Outcome Pathway on Aryl hydrocarbon receptor activation leading to uroporphyria Amani Farhat ... [et al] |
| title_full_unstemmed | Adverse Outcome Pathway on Aryl hydrocarbon receptor activation leading to uroporphyria Amani Farhat ... [et al] |
| title_short | Adverse Outcome Pathway on Aryl hydrocarbon receptor activation leading to uroporphyria |
| title_sort | adverse outcome pathway on aryl hydrocarbon receptor activation leading to uroporphyria |
| topic | Environment Social Issues/Migration/Health |
| topic_facet | Environment Social Issues/Migration/Health |
| url | https://doi.org/10.1787/fde13d2c-en |
| work_keys_str_mv | AT farhatamani adverseoutcomepathwayonarylhydrocarbonreceptoractivationleadingtouroporphyria AT manninggillian adverseoutcomepathwayonarylhydrocarbonreceptoractivationleadingtouroporphyria AT obrienjason adverseoutcomepathwayonarylhydrocarbonreceptoractivationleadingtouroporphyria AT kennedyseanw adverseoutcomepathwayonarylhydrocarbonreceptoractivationleadingtouroporphyria |